PINE BROOK, N.J., March 10 /PRNewswire/ -- Elusys Therapeutics, Inc.
(Elusys), a privately held biopharmaceutical company developing
antibody-based therapies for the treatment of life-threatening infectious
diseases, today announced the appointment of Robert Gundel, Ph.D., M.B.A.,
as Vice President of Research.
Elizabeth G. Posillico, Ph.D., President and Chief Executive Officer,
commented on the appointment, "On behalf of Elusys' Board of Directors and
management, I am very pleased to welcome Bob to our executive management
team. As Vice President of Research, he will play a key role in helping to
further develop and advance our corporate and scientific strategies. With
more than twenty-five years of experience in developing monoclonal
antibody-based products from both the biotech and pharmaceutical sectors,
Dr. Gundel will lead our existing R&D team to further the development of
our antibody based products for the treatment of infectious disease. He
will also use his expertise to evaluate new product opportunities and will
play a key leadership role in managing our existing and future R&D
collaborations."
Prior to joining Elusys, Dr. Gundel held executive management positions
at a number of leading biopharmaceutical companies including, Bayer,
Chiron, XOMA and ARIUS. Most recently, Dr. Gundel served as Chief
Scientific Officer at ARIUS Research, Inc., a biotechnology company focused
on the discovery and development of therapeutic antibodies for the
treatment of cancer and other diseases. At ARIUS, he managed the drug
discovery and development programs and worked to broaden the company's
targeted therapeutic areas by identifying and developing new programs
outside of oncology. He also identified new technologies to keep the
company ahead of the curve for therapeutic drug discovery, development and
manufacturing.
Previously, Dr. Gundel was Vice President, Preclinical Research and
Scientific Corporate Development at XOMA (US), LLC, a biotechnology company
specializing in the discovery, development and manufacturing of therapeutic
antibodies. At XOMA, he directed preclinical research and coordinated
discovery and development activities in a number of therapeutic areas,
including infectious diseases, inflammatory disorders and cancer.
Dr. Gundel also served as Vice President, Pharmacology and Preclinical
Research at Chiron Corporation, where he supervised efforts to identify and
characterize novel therapeutics for inflammatory diseases. Earlier, Dr.
Gundel worked at Bayer Corporation where he held various positions within
the Biotechnology Unit including Director of Pharmacology. He began his
career in pharmaceutical R&D at Boehringer Ingelheim Pharmaceuticals, Inc.,
where he supervised efforts to identify and characterize novel therapeutics
for inflammatory diseases.
Dr. Gundel earned his M.B.A. from Saint Mary's College, and his Ph.D.
in physiology from New York Medical College. He has participated in over 45
national and international scientific meetings as an invited speaker and/or
session chairperson. He has published more than 60 articles in peer
reviewed journals and book chapters, served on the editorial board of
several journals and is a co-inventor on several issued U.S. patents.
About Elusys
Elusys is a privately held biopharmaceutical company focused on the
development of antibody-based therapeutics for the treatment of life-
threatening infectious diseases. In March of 2007, the company's anthrax
antibody therapeutic, Anthim, was selected to R&D Directions' list of "100
Great Investigational Drugs." Current venture investors include Essex
Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures,
MedImmune Ventures and Pfizer. For more information please visit
http://www.elusys.com.
SOURCE Elusys Therapeutics, Inc.
 back to top
Related links:
http://www.elusys.com
CONTACT:
Tim Allison of LaVoie Group for Elusys
Therapeutics, Inc., +1-978-745-4200 Ext. 102,
Tallison@lavoiegroup.com
|
